Relationship between serum concentration and daily dose of dantrolene in cerebral palsy patients.
Serum concentration of dantrolene and its active metabolite, 5-hydroxydantrolene were determined in 27 cerebral palsy patients. Correlation coefficients between the oral dose of dantrolene and serum levels of dantrolene and its major metabolite, 5-hydroxydantrolene were rather small in cerebral palsy patients. The mean half-times of dantrolene and 5-hydroxydantrolene were 3.41 (n = 6) and 4.00 (n = 5) hours, respectively. These values were about a half of those reported earlier [Lietman et al., 1974; Meyler et al., 1979; Flewellen et al., 1983]. The poor correlation between serum level and dose may be due to the variation in an extent of oral dantrolene availability.
D000293:Adolescent; D000328:Adult; D002547:Cerebral Palsy / Q000097:blood / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003620:Dantrolene / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate
C034271:5-hydroxydantrolene; D003620:Dantrolene